Introduction
============

Human and mouse WW domain-containing oxidoreductase, designated WWOX, FOR, or WOX1, has been generally regarded as a tumor suppressor since its discovery in 2000 ([@B12]; [@B100]; [@B35]). Human *WWOX* gene is located on a common fragile site *FRA16D*, spanning 1.1 million bases on chromosome ch16q23.3-24.1. *WWOX* is composed of 9 exons with an open reading frame (ORF) of 1245 base pairs long, encoding a 414-amino-acid (46 kDa) protein. *WWOX* gene possesses multiple long non-coding RNA *PARTICLE* (Gene *PARTICL*- '*P*romoter of *MAT2A*-*A*ntisense *R*adia*T*ion *I*nduced *C*irculating *L*ncRNA) triplex clusters, suggesting its control of gene expression in the genome ([@B93]). WWOX protein possesses two *N*-terminal WW domains, a nuclear localization signal between the WW domains, a *C*-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, and a proapoptotic *C*-terminal tail termed D3 ([@B12]; [@B100]; [@B35]; [@B60]; [@B80]; [@B1], [@B2]; [@B65]).

The WW domain participates in protein/protein interactions for transducing signals ([@B34]; [@B87]; [@B98]). The first WW domain of WWOX binds PPxY or PPPY-containing proteins (e.g., p73, ErbB-4, SIMPLE, WWBP1, WWBP2, Ezrin, AP-2g, Runx-2, and many others) ([@B83]; [@B68]; [@B34]; [@B87]; [@B98]). When Tyr33 in the first WW domain is phosphorylated, activated WWOX acquires an enhanced capability in binding a broad spectrum of proteins ([@B34]; [@B98]), including p53 ([@B35], [@B30],[@B31], [@B32],[@B33], [@B34]), c-Jun *N*-terminal kinase (JNK) ([@B30]), Zinc finger-like protein that regulates apoptosis (Zfra) ([@B60]), c-Jun and cAMP response element binding protein (CREB) ([@B79]) and others. The second tandem WW domain assists synergistically with the first WW domain in enhancing the protein/protein binding ([@B47]). Transiently overexpressed WWOX frequently sequesters transcription factors in the cytoplasm, and thereby blocks their transcription for prosurvival proteins in the nucleus in cancer cells *in vitro* ([@B48]). In contrast, endogenous WWOX binds and co-translates with many transcription factors to relocate to the nucleus to enhance or block neuronal survival under sciatic nerve dissection ([@B79]). Endogenous trafficking protein particle complex 6A (TRAPPC6A) acts as a carrier for WWOX to undergo nuclear translocation ([@B26]). Indeed, WWOX works together with many transcription factors to either support neuronal survival or death under physiological or pathological conditions.

Tyr33-Phosphorylated WWOX in Apoptosis and in Temperature-Related Bubbling Cell Death (BCD)
===========================================================================================

The proapoptotic function of WWOX has been previously reviewed ([@B27], [@B28]; [@B31], [@B34]; [@B65]). Briefly, UV irradiation activates cytosolic WWOX via Tyr33 phosphorylation (pY33-WWOX), followed by binding Ser46-phosphorylated p53. Both proteins relocate to the mitochondria or nuclei to induce cell death ([@B30], [@B32]). As an inhibitor, JNK or Zfra suppresses WWOX in inducing apoptosis ([@B30]; [@B60]; [@B3]). Zfra acts by reducing Tyr33 phosphorylation in WWOX ([@B60]). Zfra binds the *N*-terminal WW domain and *C*-terminal SDR domain of WWOX. This binding interferes with Tyr33 phosphorylation by tyrosine kinase Src ([@B7]).

At temperatures lower than 37°C, WWOX is needed for a recently described type of cell death, designated bubbling cell death ([@B36]; [@B29]). BCD is not apoptosis, necroptosis, or necrosis. When cells are subjected to UV irradiation and cold shock followed by culturing at 37°C, the cells undergo apoptosis (e.g., caspase activation, whole cell and nuclear condensation, DNA fragmentation, etc.). However, if the UV/cold shock-treated cells are incubated at a lower temperature (e.g., 4, 10, or 22°C), they generate, in most cases, a nuclear nitric oxide (NO)-containing bubble per cell. Some cells may generate 2--3 bubbles. The bubble continues to inflate and finally is released from the cell membrane. The cells die later on. Membrane phosphatidylserine flip over, caspase activation and DNA fragmentation, which are found in apoptosis, are not involved in BCD. Raising the temperature back to 37°C resumes the event to apoptosis. If cells are devoid of WWOX (e.g., *Wwox*^-/-^ MEF), cell death is retarded ([@B36]; [@B29]). Overall, UV energy is absorbed by the nucleus, and cold shock assists the rapid relocation of cytosolic p53, WWOX, and NOS2 to the nucleus. Nitric oxide synthase NOS2 is responsible for the bubble generation that leads to cell death ([@B36]; [@B29]).

Activated WWOX Induces Cell Death From the Mitochondria and Nuclei
==================================================================

WWOX in Neuronal Injury
-----------------------

Constant light-induced retinal neural degeneration involves WWOX activation and pY33-WWOX accumulation in the mitochondria and nuclei to cause damage and death ([@B37]). Neurotoxin MPP^+^ (1-methyl-4-phenylpyridinium) also induces pY33-WWOX upregulation and nuclear accumulation to cause neuronal death in rats ([@B82]). During the acute phase of sciatic nerve dissection, pY33-WWOX, along with its interacting transcription factors, becomes accumulated in the nucleus that leads to the rapid death of the large-sized neurons *in vivo* ([@B79]). WWOX blocks the prosurvival function of CREB-, CRE-, and AP-1-mediated promoter activation *in vitro* ([@B79]). In stark contrast, WWOX enhances the promoter activation governed by c-Jun, Elk-1 and NF-κB ([@B79]). Apparently, a balance in the protein levels for WWOX and transcription factors is critical in determining the fate of dissected neurons.

Hyal-2/WWOX Signaling in Traumatic Brain Injury (TBI) Links to BCD
------------------------------------------------------------------

WWOX localizes in many subcellular compartments, including cell membrane, mitochondrion, lysosome, nucleus, and others. WWOX does not have a membrane localization signal. It is anchored, in part, to the membrane/cytoskeleton area by hyaluronidase Hyal-2 ([@B64], [@B62], [@B63]) and Ezrin ([@B68]). WWOX acts as a transducer in many stress-related signal pathways induced by tumor necrosis factor (TNF), chemotherapeutic drugs, UV irradiation ([@B34], [@B25], [@B34], [@B26]; [@B1]), Wnt/β-catenin ([@B16]), transforming growth factor-β (TGF-β) ([@B64]; [@B25]), complement C1q ([@B61]), hyaluronan and Hyal-2 ([@B25]; [@B62], [@B63]), sex steroid hormones ([@B111]), T cell differentiation reagents ([@B66]), and others.

During TBI, activation of the Hyal-2/WWOX/Smad4 signaling complex causes neuronal death ([@B63]) (**Figure [1A](#F1){ref-type="fig"}**). Hyal-2 and WWOX are accumulated in the nuclei of damaged neurons in rat brain ([@B63]) (**Figure [1A](#F1){ref-type="fig"}**). Hyal-2 is a cognate receptor for hyaluronan and TGF-β1 ([@B64], [@B62], 2017). Both hyaluronan and TGF-β1 may utilize the Hyal-2/WWOX/Smad4 signaling to enhance the cell survival or death. It has been shown that long-term overexpression of TGF-β1 causes neurodegeneration in mice ([@B119]).

![Potential role of WWOX and BCD in neuronal death during traumatic injury. **(A)** Needle insult to the brain was carried out in rats. Post injury for 3 and 24 h, the animals were sacrificed. By immunoelectron microscopy, accumulation of Hyal-2 and WWOX is found in the nuclei of dying neurons in the brain cortex ([@B63]). **(B)** Nuclear accumulation of Hyal-2 and WWOX leads to BCD ([@B36]). Both schematic graphs and a real-time image are shown. If p53 competes with Hyal-2 to complex with WWOX, both p53/WWOX proteins are retained in the cytoplasm and the extent of Hyal-2/WWOX complex is reduced, no BCD occurs ([@B63]). (Data in **A** is adapted from [@B63], republishing according to the guideline of *Oncotarget*).](fnins-12-00563-g001){#F1}

Bubbling cell death can also occur at 37°C. For example, when cells are transiently overexpressed with hyaluronidase Hyal-2 and WWOX followed by treating with high-molecular-weight hyaluronan, BCD occurs at 37°C ([@B63]) (**Figure [1B](#F1){ref-type="fig"}**). Hyaluronan binds membrane Hyal-2 to initiate the Hyal-2/WWOX signaling, and that both Hyal-2 and WWOX are accumulated in the nuclei. It is reasonable to assume that during TBI, the nuclear Hyal-2 and WWOX may exert BCD due to the production of NO. Formation of nuclear bubbles in the dying neurons *in vivo* is unknown. However, bubble formation *in vivo* is difficult to detect, because it is technically impossible to fix bubbles for microscopic examination. Reactive oxygens species (ROS) are rapidly upregulated during TBI ([@B11]). WWOX, via its *C*-terminal SDR domain, controls the generation of ROS in *Drosophila* ([@B92]) and mammalian cells ([@B41]). Also, the SDR domain of WWOX controls the cellular outgrowths caused by genetic deficiencies of the components of the mitochondrial respiratory complexes in *Drosophila* ([@B40]). Under physiologic conditions, oxidative phosphorylation sustains WWOX expression ([@B41]). However, when glycolysis (or Warburg metabolism) goes up in aberrant cells, WWOX expression is downregulated ([@B41]). Reduced WWOX levels in *Drosophila* allow cellular outgrowths to various extent caused by genetic deficiencies of components of the mitochondrial respiratory complexes and aberrant ROS production ([@B40]). Together, WWOX participates in TBI and this is related with ROS generation and brain tissue repair.

WWOX in Neurodegeneration *In Vivo*
===================================

Pathological Features in Neurodegeneration
------------------------------------------

Neurodegenerative diseases (NDs) encompass a heterogeneous group of chronic progressive diseases, each affecting specific central nervous system (CNS) compartment. The pathologies of NDs are not specific for each individual disease. Neurofibrillary tangles and Lewy bodies, for example, may appear in non-demented and non-idiopathic Parkinson disease patients. Also, the pathological or clinical features may overlap. Over the past decades, many animal models have been established to seek potential propagation mechanisms and associated risk factors for NDs ([@B86]; [@B90]; [@B44]; [@B53]; [@B39]). Aging-related stress, oxidative stress, reduced mitochondrial function, altered subcellular transport, and activation of the ER stress and unfolded protein response (UPR) pathways are considered important during neurodegeneration ([@B86]; [@B53]).

In the aging processes, chaperones may become dysregulated and the degradation machineries stop working properly, which leads to protein misfolding, aggregation, and accumulation for neuronal damage. Among these, UPR exists in the mitochondria and the endoplasmic reticulum, along with disordered cytosolic heat shock response, ubiquitin-proteasome system, and autophagy ([@B117]; [@B53]). Presence of aberrant protein aggregates, inclusion bodies and/or tangled fibrous proteins in the aging neurons, glial cells, and brain matrix is the pathological hallmarks of neurodegeneration ([@B101]; [@B99]; [@B58]). Furthermore, formation and spread of prion-like Aβ aggregates occur during AD progression, and this is not due to overexpression of APP (amyloid precursor protein) ([@B103]). Prion protein in the exosomes facilitates the spreading and aggregation of neurotoxic Aβ ([@B54]).

WWOX Deficiency Leads to Severe Neural Damage and Metabolic Disorders
---------------------------------------------------------------------

The WWOX protein is heterogeneously expressed in the central nervous system. WWOX-positive stains are found in the human cerebrum, specifically in the pyramidal neurons and astrocytes from the frontal and occipital cortices, and in the nucleus caudate, pons and nuclei olivaris of medulla. Neuropils and small neurons are also immunoreactive to WWOX antibody. However, parietal, limbic and temporal cortices and substantia nigra are minimal or negative for WWOX immunoreactivity ([@B91]). In the developing mouse brain, WWOX protein expression is essentially present in every brain region and the expression level is reduced in the newborns ([@B38]). In the adult brain, WWOX is abundant in the epithelial cells of the choroid plexus and ependymal cells, while a low to moderate level of WWOX is observed within white matter tracts, such as axonal profiles of the corpus callosum, striatum, optic tract, and cerebral peduncle ([@B38]).

Despite its role in cell death, WWOX is essential in homeostasis *in vivo*. *WWOX*/*Wwox gene* deficiency severely affects normal physiological functions, especially in embryonic neural development ([@B38]; [@B4]; [@B22], [@B26]; [@B115]). Deficiency of *WWOX*/*Wwox* gene due to point mutations or homozygous nonsense mutation may result in childhood onset autosomal recessive cerebellar ataxia and epilepsy, growth retardation, microcephaly with seizure, retinal degeneration, and early death at 16 months of age ([@B120]; [@B5]; [@B45]). Similar observations are shown in rats ([@B112]).

*WWOX* gene is involved in the regulation of lipid homeostasis and metabolism ([@B83], [@B84]; [@B73]; [@B124]; [@B41]; [@B67]; [@B78]; [@B1]; [@B2]). *WWOX* gene alteration is associated with the low plasma high-density lipoprotein cholesterol (HDL-C) levels and aberrant HDL-C and triglyceride levels ([@B73]; [@B104]). Furthermore, whole body and liver conditional *Wwox* knockout mice revealed a significant role for *Wwox* in regulating HDL and lipid metabolism ([@B67]).

Interference in lipid metabolism may be a critical contributor in the pathogenesis of neurological diseases. For example, WWOX is not expressed in the lipid-rich myelin sheath in the normal neurons, but activated pY33-WWOX is accumulated in the myelin sheath during neurotoxin MPP^+^-induced neuronal death ([@B82]). While both apolipoprotein E (Apo E) and WWOX are involved in AD and TBI, the functional relationship between these two proteins (e.g., binding) needs further elucidation. Taken together, WWOX plays a crucial role in neural development and lipid metabolism. Without WWOX, severe neural diseases, metabolic disorders and early death occur in humans and animals.

*WWOX* Gene Expression in the Brain
-----------------------------------

By analyzing the database in the Allen Brain Atlas^[1](#fn01){ref-type="fn"}^, *WWOX* gene expression levels are shown to be significantly downregulated in the postmortem normal hippocampus, compared to those in the pons and white matter (*n* = 6; age 42.5 ± 13.4; 3 Caucasians, 2 blacks, 1 Hispanic) (**Figure [2A](#F2){ref-type="fig"}**). There were only six normal brain samples exhibiting detectable signals for *WWOX* gene expression (as shown in the **Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). *WWOX* gene expression is upregulated in the cingulum bundle of the white matter by 2.31-fold, and the central glial substance of the myelencephalon by 2.78-fold.

![*WWOX* gene and protein expression in human brain. **(A)** *WWOX* gene expression was analyzed using the database in the Allen Brain Atlas (<http://www.brain-map.org>). Detectable signals for *WWOX* gene expression were found in six postmortem normal individuals (age 42.5 ± 13.4; 3 Caucasians, 2 blacks, 1 Hispanic). Representative *WWOX* gene expression levels in the brain white matter, pons and hippocampus are shown. Also, see the **Supplementary Table [S1](#SM1){ref-type="supplementary-material"}** for *WWOX* gene expression in the normal brains (around one-fold changes for all indicated regions). **(B,C)** In the "Possible AD" and "Traumatic Brain Injury" groups (77--100+ years old), *WWOX* gene expression levels are shown in the indicated brain areas. **(D,E)** Expression of wild type WWOX (46 kDa) and isoform WWOX2 (41 kDa) is downregulated in the neurons of AD hippocampi compared with normal controls (a representative set from five immunostains; magnification, 200×; data from [@B114]). **(F)** In AD patients, the protein levels for WWOX (*n* = 8), isoform WWOX2 (*n* = 8), and pY33-WWOX (*n* = 6) are significantly downregulated in the hippocampi as determined by Western blotting, compared to age-matched controls (∼32 ± 5% reduction, *p* \< 0.005; data with minor revisions for the art work are adapted from [@B114]; republishing according to the guideline of the *Journal of Biological Chemistry*).](fnins-12-00563-g002){#F2}

In the "Possible AD" group (77 to 100+ years old), *WWOX* gene expression levels are barely changed in the hippocampus (**Figure [2B](#F2){ref-type="fig"}**). Also, compared to the hippocampus, *WWOX* gene expression is significantly downregulated in the parietal and temporal neocortex, but is significantly upregulated in the white matter of the forebrain (**Figure [2B](#F2){ref-type="fig"}**). Interestingly, similar expression profiles are observed in the "Traumatic Brain Injury (TBI)" group (77 to 100+ years old; **Figure [2C](#F2){ref-type="fig"}**).

Also, in other gene databases (GTEx, Illumina, BioGPS, and CGAP SAGE, as summarized in the GeneCard^[2](#fn02){ref-type="fn"}^), *WWOX* gene expression levels in the brain, cerebellum, cortex, spinal cord and tibial nerve are similar to those from other tissues and organs in normal humans. However, WWOX protein expression levels are significantly increased in the human fetal brains (GeneCard database shown above). This is in agreement with our observations using mouse fetal brains ([@B38]).

WWOX Protein Downregulation in Alzheimer's Disease (AD)
-------------------------------------------------------

It is generally agreed that gene expression cannot always correlate with protein expression. The aforementioned *WWOX* gene expression levels do not correlate positively with the extent of WWOX protein expression. For example, downregulation of *WWOX* gene occurs in the hippocampi of young adults (**Figure [2A](#F2){ref-type="fig"}**) and many other areas (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). However, WWOX protein expression levels are detectable in neurons of many regions in the brain ([@B91]).

Indeed, significant downregulation of the protein level for WWOX, isoform WWOX2, and pY33-WWOX has been shown in the hippocampi of AD patients, compared to age-matched controls ([@B114]) (**Figures [2D](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}**). However, during sciatic nerve injury, rapid upregulation of *Wwox* gene expression occurs in less than 30 min in the neurons of dorsal root ganglion, followed by significant upregulation of WWOX protein and its Tyr33 phosphorylation in the damaged neurons in 24 h ([@B79]). Activated WWOX is needed to initiate neuronal death in the damaged tissue.

There is no positive correlation between *WWOX*/*Wwox* mRNA expression and protein expression. For example, translational blockade of *Wwox* mRNA has been shown in the development of skin squamous cell carcinoma (SCC) in hairless mice ([@B72]). During the acute exposure of hairless mice to UVB, both WWOX and pY33-WWOX proteins are upregulated in epidermal cells in 24 h. SCCs then start to develop in 3 months. There are significant reductions in WWOX and pY33-WWOX proteins in the SCC cells. However, no downregulation of *Wwox* mRNA occurs ([@B72]). In SCC patients, significant reduction of WWOX and pY33-WWOX proteins are observed in non-metastatic and metastatic cutaneous SCCs, whereas no downregulation of *WWOX* mRNA occurs ([@B72]). Together, *WWOX/Wwox* mRNA is subjected to translational blockade in the skin and probably other tissues and organs under pathological conditions.

WWOX Control of Neuronal Survival via Binding and Suppressing Tau and Tau Hyperphosphorylating Enzymes
------------------------------------------------------------------------------------------------------

Compelling evidence reveals that WWOX is likely to slow down neurodegeneration such as in AD. For example, the *C*-terminal SDR domain of WWOX binds and limits the enzymatic activity of glycogen synthase kinase 3β (GSK-3β) ([@B114]; [@B122]) (**Figure [3](#F3){ref-type="fig"}**). GSK-3β is known to hyperphosphorylate Tau which leads to restriction of neurite outgrowth, and prevention of neuronal differentiation resulting in formation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in AD ([@B9]; [@B10]; [@B22]; [@B81]; [@B114]). WWOX binds Tau via its SDR domain ([@B114]) (**Figure [3](#F3){ref-type="fig"}**), and prevents enzyme-dependent Tau hyperphosphorylation ([@B114]). WWOX contains two potential GSK-3β-binding FXXXLI/VXRLE motifs ([@B122]). Precisely, the α-helical segment (amino acids \#388 to 407) at the SDR domain of WWOX interacts physically with the GSK3β binding-pocket *α*-helix (amino acid \#262 to 273) ([@B122]). Transiently overexpressed WWOX inhibits GSK-3β-stimulated S396 and S404 phosphorylation within the microtubule domains of Tau. Consequently, WWOX represses GSK-3β activity in hyperphosphorylating tau, restores tau's ability to assemble the microtubule network, and promotes neurite outgrowth in neuroblastoma SH-SY5Y cells. When WWOX is knocked down by small interfering RNA, retinoic acid is not able to mediate differentiation of SH-SY5Y cells (e.g., neurite outgrowth) ([@B122]).

![WWOX limits Tau hyperphosphorylation and aggregation. The *C*-terminal SDR domain of WWOX physically binds GSK3β preventing hyperphosphorylation of Tau ([@B114]; [@B122]). Also, the first WW domain binds JNK, thereby preventing Tau hyperphosphorylation ([@B114]). The first WW domain binds ERK ([@B66]). Tau protein supports polymerization of tubulin monomers to assemble microtubules, which are needed for neurite outgrowth ([@B122]).](fnins-12-00563-g003){#F3}

The WWOX also binds JNK via its Tyr33-phosphorylated first WW domain, and the binding results in neutralization of the functions of both proteins in a reciprocal manner ([@B30]) (**Figure [3](#F3){ref-type="fig"}**). Additionally, the first WW domain of WWOX physically interacts with ERK (extracellular signal-regulated kinase) ([@B65]). ERK has been implicated in Tau hyperphosphorylation ([@B9]) (**Figure [3](#F3){ref-type="fig"}**). Cyclin dependent kinase 5 (Cdk5) hyperphosphorylates many substrates such as amyloid precursor protein, tau and many other proteins in the brain ([@B109]); however, functional interaction between WWOX and CDK5 has never been documented.

TIAF1 and TRAPPC6AΔ Protein Aggregates in the Hippocampi of Mid-Aged Normal Individuals
---------------------------------------------------------------------------------------

In an inducible transgenic mouse model, neuron-specific expression of TGF-β in the neocortex, hippocampus and striatum for a long term results in deposition of amyloid fibrils in these brain areas ([@B119]). Deposits of apolipoprotein E (ApoE) are also found in perivascular areas ([@B119]). When TGF-β induction stops, the amyloid and ApoE aggregates stably remain in the brain and vascular lesions. We have discovered a few novel proteins, whose aggregation is found in the brain hippocampal and cortical areas of both non-demented healthy individuals and demented AD patients. [T]{.ul}GF-β1-[i]{.ul}nduced [a]{.ul}ntiapoptotic [f]{.ul}actor 1 (TIAF1; 12 kDa) is involved in the pathogenesis of AD and cancer, as well as in allograft rejection by activated T helper cells ([@B121]; [@B74]; [@B59]; [@B23]). Presence of aggregated TIAF1 protein in the dead neurons is shown in the hippocampi of middle-aged normal humans ([@B74]; [@B23]). Notably, little or no Aβ aggregates are found in the TIAF1 plaques in the mid-aged humans ([@B74]) (**Figure [4A](#F4){ref-type="fig"}**). For example, TIAF1 aggregation is detected in 59% of non-demented control hippocampi (age 59.0 ± 17.0, *n* = 41), and only 15% of the total samples have Aβ aggregates, as determined by filter retardation assay ([@B74]). However, 54% of TIAF1 aggregation is shown in the hippocampi of older postmortem AD patients (age 80.0 ± 8.8, *n* = 97), in which 48% of the total AD samples possess Aβ aggregates. Presence of a representative TIAF1-containing plaque from the hippocampus of a 9-month-old APP/PS1 transgenic mouse is shown (**Figure [4B](#F4){ref-type="fig"}**). A minimal amount of Aβ aggregates is found within the center of the plaque. The observations imply that TIAF1 aggregates are difficult to remove with age by the ubiquitination/proteasomal degradation system. *In vitro* analysis revealed that TIAF1 undergoes self-polymerization and this leads to amyloid β formation ([@B74]). Together, TIAF1 aggregation occurs in the middle age and this may result in slow formation of amyloid β in humans ([@B74]).

![TPC6AΔ and TIAF1 in a cascade of protein aggregation and WWOX blocks the aggregation. **(A)** Representative human AD hippocampal tissue sections were pre-stained with Bielschowsky stain, followed by staining with specific antibody against TIAF1 (green), and Aβ (red) and DAPI for nuclei. A representative confocal image of a plaque is shown ([@B74]). **(B)** Shown is a TIAF1-containing plaque from a hippocampal section of a 9-month-old APP/PS1 transgenic mouse, containing Aβ aggregates in the center ([@B74]). **(C)** In representative human brain cortical tissue sections from AD patients and age-matched controls, a pS35-TPC6AΔ-containing plaque is shown. In negative controls, the immunizing peptide blocks the immunoreactivity ([@B26]). **(D,E)** Presence of pS35-TPC6AΔ and pT181-Tau aggregates is shown in the cortex and hippocampus of 3-week-old *Wwox* knockout mice ([@B26]). **(F)** Endogenous TPC6A and TPC6AΔ shuttle between nucleoli and mitochondria. Ser35 phosphorylation supports shuttling from the nucleus to the nucleolus, and Tyr112 phosphorylation is needed for translocation from the nucleolus to the mitochondrion ([@B23]). **(G)** Upon WWOX downregulation, a sequential protein aggregation cascade occurs. When WWOX level is reduced, pS35-TPC6AΔ starts to polymerize and recruit pS37-TIAF1 for further polymerization and accumulation in the outer membrane of mitochondria ([@B23]; [@B26]). The aggregated pS35-TPC6AΔ and pS37-TIAF1 cause caspase 3 activation and cytochrome c release. The activated caspase 3 leads to APP degradation and formation of Aβ and amyloid fibrils and Tau tangles. SH3GLB2 aggregation ([@B75]) occurs probably right after that of pS37-TIAF1. (All data are adapted with revisions in art work from [@B74]; [@B23]; [@B26], under the guidelines of the publishers).](fnins-12-00563-g004){#F4}

TGF-B-induced TIAF1 self-aggregation leading to the formation of Aβ aggregates probably occurs via a signaling pathway independently of the type II TGF-β receptor ([@B74]; [@B59]; [@B23]). TGF-β binds membrane Hyal-2 to initiate a non-canonical Hyal-2/WWOX/Smad4 pathway ([@B64], [@B62], 2017). TIAF1 physically binds Smad4 and strongly suppresses SMAD-regulated promoter activation, and Smad4 blocks TIAF1 aggregation caused by TGF-β ([@B74]). In addition, p53 binds TIAF1. In the absence of TIAF1, pS15-p53 fails to undergo nuclear translocation ([@B108]). Interestingly, without p53, self-aggregating TIAF1 spontaneously activates the SMAD-regulated promoter to cause cell death ([@B24]).

Under physiologic conditions, TGF-β1 promotes binding of TIAF1 with Smad4, and the TIAF1/Smad4 complex co-relocates to the nucleus and modulates gene transcription ([@B74]; [@B24]; [@B59]). This normal signaling event does not cause protein aggregation. However, under aberrant signaling, TGF-β1 causes TIAF1 aggregation and reduces its binding with membrane APP, thus leading to APP de-phosphorylation at Thr688 and then degradation and production of amyloid β monomer, intracellular domain of the APP intracellular domain (AICD), and amyloid fibrils ([@B56]; [@B74]; [@B24]; [@B59]). Presence of aggregated TIAF1 in the peritumor coats of metastatic brain tumor cells does not cause cancer cell death ([@B74]; [@B24]; [@B59]). However, the coat-associated TIAF1 aggregates are cytotoxic to neurons ([@B74]).

TRAPPC6AΔ Protein Aggregation Is Upstream of TIAF1
--------------------------------------------------

We have identified a TGF-β-induced trafficking protein particle complex 6A (TRAPPC6A or TPC6A) ([@B23]; [@B26]). *TRAPPC6A*/*Trappc6a* gene is associated with skin pigment formation in mice ([@B51]), AD in humans ([@B52]), and other neural diseases ([@B88]). An intra-*N*-terminal deletion isoform of TRAPPC6A, designated TRAPPC6AΔ or TPC6AΔ, tends to spontaneously form aggregates or plaques in the extracellular matrix of the hippocampi of postmortem middle-aged normal humans and older AD patients (**Figure [4C](#F4){ref-type="fig"}**) and 3-week-old *Wwox* gene knockout mice (**Figure [4D](#F4){ref-type="fig"}**) ([@B23]; [@B26]). Presence of pT181-Tau, a marker for tau phosphorylation and aggregation in mice, is also shown in the cortex of *Wwox* knockout mice, but is barely detectable in the wild type and heterozygous *Wwox* mice (**Figure [4D](#F4){ref-type="fig"}**). Conceivably, without WWOX, cellular proteins tend to undergo aggregation.

TPC6A aggregates are also present in the human brain cortex and hippocampus, which are ∼50 and 40% positive, respectively, for both control (59 ± 17 years old; *n* = 42) and AD (80 ± 8.8 years old; *n* = 96) groups ([@B26]), suggesting that the aggregated proteins are stable and hard to undergo degradation with age. In comparison, protein aggregates for pY33-WWOX are significantly reduced by ∼40% in the AD samples, compared to non-demented controls ([@B26]). Again, compared with the non-demented controls, tangled tau and Aβ aggregates are significantly increased in the AD samples ([@B26]). If our observations hold true, TPC6AΔ/TIAF1 starts polymerization in the middle age, and takes at least 10--40 years to generate significant amounts of tau and amyloid β protein aggregates for clinically defined AD symptoms.

We have recently determined that endogenous TPC6A undergoes a novel mitochondrion-nucleolus shuttling (**Figure [4F](#F4){ref-type="fig"}**) ([@B23]). TGF-β1 causes nuclear TPC6A to undergo Ser35 phosphorylation, followed by entering the nucleoli and then relocating to the mitochondria as a dimer, which probably requires phosphorylation at Tyr112. The mitochondrial TPC6A shuttles back to the nucleolus. TPC6A carries WWOX to the nucleus.

TPC6AΔ protein possesses an internal frame deletion of amino acids \#29--42 at the *N*-terminus. Wild type TPC6A is less likely to undergo aggregation. Both TPC6A and TPC6AΔ proteins are able to shuttle between nuclei and mitochondria ([@B23]; [@B26]). Under aberrant signaling, TPC6AΔ molecules are accumulated as aggregates in the mitochondria, where TIAF1 binds TPC6AΔ. Both proteins induce caspase activation and apoptosis (**Figure [4G](#F4){ref-type="fig"}**) ([@B23]; [@B26]). A BAR domain-containing SH3GLB2 (SH3 Domain Containing GRB2 Like, Endophilin B2) is a potential downstream protein for aggregation via direct binding with TIAF1 ([@B95]) (**Figure [4G](#F4){ref-type="fig"}**). Aggregation of SH3GLB2 can be found in the brain cortex and hippocampus ([@B75]).

WWOX Controls TRAPPC6AΔ, TIAF1, and Tau Aggregation *in vivo*: Effect of TGF-β
------------------------------------------------------------------------------

The WWOX physically binds TPC6AΔ, TIAF1, and Tau and prevents their aggregation ([@B74]; [@B23]; [@B26]; [@B113]). TGF-β induces the dissociation between WWOX and TIAF1, or TPC6AΔ. The dissociated TPC6AΔ/TIAF1 aggregates cause caspase activation, APP degradation, and ultimately formation of amyloid β ([@B74]; [@B23]; [@B26]). Similarly, when WWOX protein expression is downregulated, TPC6AΔ polymerizes first and then binds TIAF1 to induce further polymerization ([@B23]; [@B26]; [@B113]) (**Figure [4G](#F4){ref-type="fig"}**).

Also, knockdown of WWOX by small interfering RNA (siRNA) induces spontaneous aggregation of TPC6AΔ and TIAF1 *in vitro*. Knockdown of TPC6AΔ fails to cause TIAF1 aggregation ([@B23]), suggesting that TPC6AΔ aggregates first, followed by TIAF1 aggregation. Collectively, when WWOX is significantly downregulated, TPC6AΔ becomes phosphorylated at Ser35 and forms aggregates in the nucleus, followed by relocating to the mitochondria to bind TIAF1 and both proteins become aggregated ([@B23]; [@B113]) (**Figure [4G](#F4){ref-type="fig"}**). Thus, one line of *in vitro* evidence reveals that without WWOX, the TPC6AΔ/TIAF1 aggregates cause formation of extracellular amyloid β and intracellular Tau aggregates ([@B74]; [@B23]; [@B26]). Further, *in vivo* evidence revealed that when *Wwox* gene is knocked out in mice, aggregation of TIAF1, TPC6AΔ, amyloid β, Tau, and many other proteins occurs in the brains in less than 3 weeks ([@B23]; [@B26]) (**Figures [4A](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}**). Taken together, WWOX plays a role in limiting protein aggregation *in vivo*.

WWOX Phosphorylation at Ser14 and Its Potential Role in Neurodegeneration
-------------------------------------------------------------------------

Site-specific WWOX phosphorylation is associated with cell differentiation and many other events ([@B66]; [@B65]). During forced cell differentiation, WWOX rapidly undergoes phosphorylation at Ser14 in leukemia cells ([@B66]; [@B65]) and in diseased organs ([@B75]). pS14-WWOX does not cause apoptosis. In contrast, overly expressed pY33-WWOX induces apoptosis ([@B34]). It suggests that the levels of pS14-WWOX and pY33-WWOX must be in a good balance *in vivo*. Under stress conditions, WWOX is phosphorylated at Tyr33 to induce apoptosis. During cell differentiation or disease progression (e.g., AD), WWOX is phosphorylated at Ser14 ([@B65]).

Ten-month-old triple transgenic (3xTg) mice for AD develop memory loss probably due, in part, to accumulated aggregates of TPC6AΔ, SH3GLB2, tau and Aβ, along with inflammatory NF-κB activation, in the hippocampal and cortical areas ([@B75]). Notably, significantly increased phosphorylation of WWOX at Ser14, but not Tyr33, is shown in their brain lesions ([@B75]). Zfra blocks Ser14 phosphorylation in WWOX, significantly reduces accumulation of TPC6AΔ, SH3GLB2, tau and Aβ aggregates, suppresses NF-κB activation, and restores memory in these mice ([@B75]). *In vitro* analysis showed that Zfra binds cytosolic proteins for accelerating their degradation in ubiquitin/proteasome-independent manner ([@B75]).

B16F10 melanoma-growing nude mice develop neuronal death in the hippocampus, amyloid plaque formation in the cortex, and melanoma infiltration in the lung in less than 2 months ([@B75]). Zfra inhibits pS14-WWOX expression in the lung and brain lesions, clears up cortical plaques, and thereby suppresses cancer growth and neuronal death ([@B75]). Together, WWOX phosphorylation at Ser14 supports the progression of neurodegeneration in the hippocampus and plaque formation in the cortex, as well as cancer progression ([@B65]).

Is WWOX a Molecular Chaperone?
------------------------------

WWOX retards neurodegeneration pathology by binding and blocking GSK-3β, ERK, JNK and probably other kinases and enhancing neurite outgrowth and neuronal differentiation ([@B114]; [@B122]). WWOX probably functions as a protein chaperone to prevent protein misfolding and degradation by the ubiquitin/proteasome system. Under stress conditions, activated WWOX with Tyr33 phosphorylation binds p53, and both proteins work synergistically to induce apoptosis ([@B32]). Without binding, p53 relocates to the cytoplasm and undergoes degradation ([@B32]). It has been proposed that the second WW domain of WWOX is an orphan module devoid of ligand binding function but is a chaperone necessary to stabilize the first WW domain in conducting protein/protein interactions ([@B47]).

Sex Steroid Hormones in Neuroprotection
=======================================

Sex steroid hormones are decreased in menopause women and aged men. Deficiency of 17-β-estradiol (E2), a major form of estrogens, is implicated in age-related cognitive decline in human and non-human primates. Estrogens modulate hippocampal synaptic spine growth, structural plasticity, and neuronal excitability, which affect long-term potentiation in learning and memory ([@B118]; [@B18]; [@B123]; [@B46]; [@B89]).

Decreased serum sex steroid hormone levels in postmenopausal women or in aged men increase the risk for developing NDs. Participation of steroid sex hormones in neuroprotection through the interaction of E2 and estrogen receptors (ER) during brain injury and neurodegeneration has been extensively investigated and very well reviewed ([@B17]; [@B8]; [@B46]).

There are two classes of ERs, namely nuclear and membrane receptors. Upon stimulation with estrogens, ERα and ERβ translocate to the nucleus, bind chromosomal DNA, and function as transcription factors ([@B110]; [@B105]; [@B20]). Membrane estrogen receptors (mERs) are mostly G protein-coupled receptors and are responsible for transducing signals upon stimulating with an estrogen. Known mERs are GPR30, ER-X, and G~q~-mER. During signaling, ERα and ERβ translocate to the nucleus and bind estrogen-responsive elements (EREs) in the promoter regions of specific genes to recruit transcriptional co-activators and co-repressors to control gene transcription ([@B110]; [@B105]; [@B20]). Alternatively, ERs act as transcriptional partners at non-ERE sites. ERs are also associated with plasma membrane lipid rafts to bind neurotransmitters and proteins, which drives the growth factor receptor signaling to interact with other neuroprotective signaling pathways or elicit redundant neuroprotection signaling (e.g., PI3K-AKT, ERK1-ERK2, and JAK-STAT3) ([@B97]; [@B8]).

ER Protective Signaling Pathways
--------------------------------

Regarding the protective signaling pathways, ERs activate the ERK and PI3K signaling cascades, which leads to the inhibition of pro-apoptotic JNK signaling and thereby protects neural tissues from damages ([@B85]; [@B69]; [@B116]). E2/ER signaling suppresses apoptosis by upregulating antiapoptotic Bcl-2 and family proteins, and downregulating proapoptotic Bcl-2 family members (**Figure [5](#F5){ref-type="fig"}**) ([@B70]; [@B125]). E2 activates PI3K via ERα and mERs. Phosphorylated PI3K activates Akt, followed by Akt phosphorylating GSK-3β at Ser9 to decrease GSK-3β activity (**Figure [5](#F5){ref-type="fig"}**) ([@B19]; [@B102]). The inhibition of GSK-3β activity is a common mechanism of neuroprotection by several factors including WWOX ([@B19]; [@B114]; [@B42]; [@B94]; [@B122]). GSK-3β inhibition-induced neuroprotection also involves β-catenin, which is regulated by E2 through the ERα/PI3K/AKT/GSK3β signaling pathway (**Figure [5](#F5){ref-type="fig"}**) ([@B42]; [@B94]). Together, these observations suggest that E2/ERs-mediated neuroprotection is mediated through the interactions of ERs with the pathways induced by different neuroprotective signaling pathways or the protective effects of growth factors.

![Role of E2/ER/WWOX in initiating protective pathways. The pathways include: Route I, E2/ER-mediated upregulation of antiapoptotic Bcl-2 family proteins, and downregulation of proapoptotic Bcl-2 family members ([@B125]) (see the route in yellow line). Route II, Activation of the pro-survival ERK/WWOX and PI3K/Akt signaling cascades to block the pro-apoptotic JNK signaling and protect the neural tissues from damages ([@B116]) (route in blue). Route III, E2 activates PI3K via ERα and mERs, followed by activating Akt to phosphorylate GSK-3β at Ser9 for functional inactivation ([@B102]) (route in green). Route IV, The SDR domain of WWOX binds and limits GSK-3β activity for neuroprotection ([@B122]) (route in light blue). Route V, Suppression of GSK-3β (e.g., by WWOX) leads to a reduced β-catenin degradation, which is regulated by E2 through the ERα/PI3K/AKT/GSK-3β signaling pathway ([@B94]) (route in purple). Route VI, In the Wnt/Frizzled signaling pathway, Wnt protein induces the activation of Dvl to block the activity of GSK-3β. Without Wnt, β-catenin is subjected to destruction by the complex of axin, APC, CK1α, and GSK-3β ([@B16]). Transiently overexpressed WWOX binds Dvl to suppress the Wnt signaling ([@B16]) (route in orange).](fnins-12-00563-g005){#F5}

WWOX as a Receptor for Sex Steroid Hormones for Signaling
=========================================================

The WWOX is a potential cytosolic or membrane receptor for sex steroid hormones ([@B33]; [@B111]). WWOX is highly expressed in hormone- or enzyme-secreting organs. WWOX is most abundant in the ductal epithelial cells such as in the breast and prostate. WWOX controls the growth and progression of breast and prostate cancers ([@B12]; [@B33]; [@B91]; [@B92]). Loss of WWOX accelerates cancer growth and metastasis. The SDR domain of WWOX is associated with aerobic metabolism and control of the generation of reactive oxygen species ([@B92]; [@B40]), which is crucial in limiting the progression of neurodegeneration ([@B111]; [@B22]).

Estrogens and Androgens Bind the SDR Domain of WWOX
---------------------------------------------------

Estrogens or androgens bind the NSYK (Asn-Ser-Tyr-Lys) motif in the *C*-terminal SDR domain of WWOX ([@B33]; [@B111]). This binding causes nuclear accumulation of activated or Tyr33-phosphorylated WWOX (pY33-WWOX) ([@B33]; [@B111]). Excessive accumulation of pY33-WWOX in the nucleus induces apoptosis. Notably, estrogen or androgen-mediated WWOX activation is independent of ERs or androgen receptor (AR), suggesting that WWOX by itself acts as a receptor ([@B33]; [@B111]). WWOX expression is significantly upregulated during the early stage of normal prostate and breast tissue progression toward hyperplasia and cancerous stages ([@B33]). Upon reaching metastatic stage, cancer cells do not express WWOX due, in part, to hypermethylation at the promoter region.

Indeed, the expression levels of WWOX positively correlate with the hormone receptor status, but negatively correlate with the clinical stages of breast and ovarian cancers ([@B33]; [@B49]). Loss of WWOX confers resistance to tamoxifen due to upregulation of ER and human epidermal growth factor receptor 2 (Her2) and their transcriptional activities ([@B50]; [@B106]). Tamoxifen is one of the estrogen receptor modulators, which regulates hormone-secreting tissue activities for treatment and prevention of ER-positive cancers. Together, these observations suggest WWOX functions as an enzyme or a receptor involved in sex steroid metabolism to modulate disease progression.

Crosstalk of ERs, WWOX, and Wnt Signaling
-----------------------------------------

Shown in the **Table [1](#T1){ref-type="table"}** is a comparison between WWOX and ERs/mERs regarding their molecular structures, actions and potential mechanisms. WWOX is involved in many signal pathways ([@B34], [@B25], 2014; [@B28]; [@B65]), and this allows its crosstalk with the signaling from ERs and mERs. For example, ERs activate the ERK1/2 and PI3K signaling cascades ([@B85]; [@B69]; [@B116]), and that WWOX physically binds ERK1/2 for supporting cell survival ([@B80]) (**Figure [5](#F5){ref-type="fig"}**) and lymphocyte differentiation ([@B66]).

###### 

Functional comparison between ER and WWOX in neurodegeneration.

                                  Estrogen receptor                                                                                                                                                WWOX                                                                                                                                                                                                         
  ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------
  Gene                            ERα-6q25.1 ([@B55]); ERβ-14q23.2 ([@B6])                                                                                                                         16q23 ([@B12]; [@B100])                                                                                                                                                                                      
  Localization in cell            Plasma membrane, cytosol, mitochondria, nucleus. ([@B110]; [@B105]; [@B116])                                                                                     Plasma membrane, cytosol, mitochondria, nucleus. ([@B34]; [@B64], [@B62])                                                                                                                                    
  Role in embryonic development   ER impact on the development of reproductive system, liver, muscle, pancreas, blood, and brain. ([@B14])                                                         Loss of WWOX related to defects in bone formation and steroidogenesis, and abnormal neural and sexual development. ([@B84]; [@B1])                                                                           
  Role in neural system           Alzheimer's disease                                                                                                                                              Inhibition of Tau hyperphosphorylation by activating PI3K/Akt to reduce GSK3β activity. ([@B19]; [@B97]; [@B8])                                                                                              Down-regulation of Tau phosphorylation through interacting with GSK-3β. ([@B114]; [@B34]; [@B122])
                                  Injury                                                                                                                                                           As a pro-survival factor by up-regulating Wnt/β-catenin signaling, PI3 kinase/Akt signaling, anti-apoptotic Bcl-2, and inhibiting microglia activation. ([@B43]; [@B96]; [@B127]; [@B94])                    As a pro-apoptotic factor through interacting with CREB, JNK, NF-κB, p53. ([@B34]; [@B79])
  Metabolic syndromes             Aberrant ERs related to imbalance of energy metabolism, homeostasis of lipid and glucose, distribution of fat, and type II diabetes. ([@B17]; [@B57]; [@B126])   Deficiency in WWOX associated with hypertension, hypoglycemia, hypocalcemia, metabolic acidosis, type II diabetes, and homeostasis of lipid and steroids. ([@B33], [@B34]; [@B91]; [@B84]; [@B92]; [@B22])   

During the signaling, E2/ER upregulates the antiapoptotic Bcl-2 family proteins and downregulates the proapoptotic Bcl-2 family members ([@B125]) (Route I, **Figure [5](#F5){ref-type="fig"}**). Also, E2/ER-mediated activation of the ERK and PI3K/Akt signaling cascades suppresses the JNK signaling for neuroprotection ([@B116]) (Route II, **Figure [5](#F5){ref-type="fig"}**).

Also, E2/ER activates PI3K and Akt to inactivate GSK-3β by phosphorylating GSK-3β at Ser9 ([@B102]) (Route III, **Figure [5](#F5){ref-type="fig"}**). WWOX via its SDR domain binds and limits GSK-3β activity ([@B122]) (Route IV, **Figure [5](#F5){ref-type="fig"}**), and this leads to a reduced β-catenin degradation regulated by E2 via the ERα/PI3K/AKT/GSK-3β signaling pathway ([@B94]) (Route V, **Figure [5](#F5){ref-type="fig"}**). GSK-3β initiates the proteasomal degradation of β-catenin by phosphorylating β-catenin on key residues (**Figure [5](#F5){ref-type="fig"}**). In addition, nuclear GSK-3β binds β-catenin, without causing β-catenin phosphorylation and degradation, but reduces the activity of β-catenin/TCF-dependent transcription via GSK-3β-Axin binding ([@B21]). GSK-3β inhibits competitive phosphorylation of β-catenin and hence facilitates the function of β-catenin, thus enabling cells with phosphorylated Tau to escape apoptosis ([@B77]).

The Wnt signaling pathway modulates amyloid β peptide-mediated neuropathology in AD by inactivating GSK-3β, which in turn prevents Tau phosphorylation ([@B13]; [@B15]) (Route VI, **Figure [5](#F5){ref-type="fig"}**). Wnt protein induces the activation of Dvl in the Wnt/β-catenin signaling to block the activity of GSK-3β. In the absence of Wnt ligand, β-catenin is destructed by the complex of axin, APC, CK1α, and GSK-3β ([@B13]; [@B15]). Ectopic WWOX sequesters cytosolic disheveled family protein (Dvl) and thus inhibits the Wnt/β-catenin pathway ([@B16]; [@B65]). WWOX suppresses the c-Jun transcriptional activity and cAMP response element-binding protein (CREB) function, which is associated with amyloid depositions ([@B107]; [@B79]).

Estrogen in the pY33-WWOX/pS15-p53 Complex
------------------------------------------

Catechol estrogens have been shown to covalently conjugate with serum proteins from diabetic patients -- the so-called "estrogenization" ([@B71]). When insulin is estrogenized, its receptor-binding pocket is blocked, thus resulting in functional blockade ([@B71]). The conserved NSYK motif in the SDR domain of WWOX is capable of interacting with androgens and estrogens and other proteins ([@B34]; [@B111]). At micromolar levels, exogenous E2 binds WWOX and induces activation of both WWOX and p53 via phosphorylation at Tyr33 and Ser15, respectively, in COS7 fibroblasts ([@B34]; [@B111]). Excessive accumulation of the E2/pY33-WWOX/pS15-p53 complex in the nucleus results in cell death ([@B34]; [@B111]). JNK1 blocks the apoptotic function of overly expressed WWOX ([@B30]).

Perspectives
============

A Focus on WWOX and Protein Aggregation in Middle Age
-----------------------------------------------------

Both aggregated tau and Aβ are considered as the key pathological markers of AD, and have been the center of focus for drug development over the past several decades. Aggregated tau and Aβ are usually found in the brain of AD patients over 70 years old while normal individuals from 40--70 years old possess very low amounts of aggregated tau and Aβ. We have determined the presence of aggregated proteins such as TPC6AD and TIAF1 in approximately 50% of the brains of mid-aged normal humans ([@B23]; [@B26]; [@B113]). Indeed, WWOX downregulation causes self-aggregation of TPC6AD and TIAF1 *in vitro* ([@B74]; [@B23]; [@B26]). *Wwox* gene knockout mice rapidly exhibit aggregation of many proteins in the brains just in 15 days after birth. These proteins include TPC6AD, TIAF1, and SH3GLB2, tau and Aβ ([@B75]). Notably, human newborns with *WWOX* deficiency rapidly develop severe neural diseases, metabolic disorders, retarded growth and early death. While TRAPPC6AΔ and TIAF1 are starters for protein aggregation, these proteins are indeed potential targets for drug development. Development of therapeutic peptides and humanized monoclonal antibodies is under way.

Zfra Initiates a Novel Immune Response to Block Protein Aggregation and Restores Memory Loss
--------------------------------------------------------------------------------------------

Zfra restores memory deficits in Alzheimer's disease triple-transgenic mice by blocking the aggregation of TPC6AΔ, SH3GLB2, Tau, and amyloid β, and reducing inflammatory NF-κB activation ([@B75]). As a WWOX-binding protein, exogenous Zfra peptide, when introduced in the circulation in mice, is mainly deposited in the spleen. Zfra binds membrane hyaluronidase Hyal-2 in non-T/non-B Z lymphocytes. Z cells then become activated to suppress cancer growth ([@B76]). Intriguingly, Z cells exhibit a memory function in killing cancer cells, even though these cells have never exposed to the cancer cells. Autologous Z cells, once activated by Zfra, are of great therapeutic use in treating cancer and probably neurodegeneration such as AD. Both full-length Zfra and a truncated 7-amino-acid Zfra4-10 are effective in suppressing cancer growth ([@B76]) and restoring memory loss ([@B75]). Since Zfra is stably retained on the Z cell surface, Zfra activates the Hyal-2/WWOX/Smad4 signaling in Z cells. Peptides or monoclonal antibodies are being developed to target membrane Hyal-2 as well as WWOX and to activate Z cells in blocking cancer and neurodegeneration.

A pTyr33-WWOX Peptide as an Agent for Blocking Neuronal Injury and Death
------------------------------------------------------------------------

Finally, an 11-amino-acid phospho-Try33 WWOX peptide was developed to block neurotoxin MPP+-induced neuronal death in the brain ([@B82]). This phospho-peptide effectively suppresses neuronal death via inhibition of JNK1 activation. In controls, non-phospho-WWOX peptide has no effect. The phospho-Try33 WWOX peptide is now being tested for its efficacy in blocking neuronal death in AD and traumatic brain injury.
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